Cambrex Invests $120 Million to Expand US API Manufacturing
Cambrex announced a $120 million investment to expand its API manufacturing capacity at its Charles City, Iowa, facility by 40%.
Cambrex
Cambrex Expands Peptide Manufacturing Capabilities in US
CDMO Cambrex announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts
Cambrex Opens New Stability Storage Facility
Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.
Cambrex Announces New Peptide Synthesis Manufacturing Technology
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Noramco Acquires Drug Product Business Unit from Cambrex
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
Cambrex Takes Snapdragon Chemistry
US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.
Cambrex Invests in US R&D Facility
Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.
Cambrex Upgrades Estonia Facility
US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s capabilities to manufacture material for clinical trials and allow early-phase projects to be developed further prior to technical transfer and scale-up.
Facing Strong Headwinds
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Cambrex Expands Swedish Drugs Facility
Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.
Flow Chemistry - A Mature Technology still on the Rise
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
Flow Chemistry: A Mature Technology still on the Rise
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
